Mini Review
Volume 13:11, 2022

Journal of
Nuclear Medicine & Radiation Therapy

ISSN: 2155-9619

Open Access

Breast Cancer Detection and Diagnosis Using Radionuclide Techniques and Instruments

Léa Berland*

Department of Chemistry and Bioengineering, University of Harvard, Cambridge, MA 02138, USA

Abstract

The diagnosis and treatment of disease make use of radioisotopes of a wide variety of elements, the majority of which are metals, in nuclear medicine. A chelator that effectively forms thermodynamically and kinetically stable complexes with the metal ions' radioisotopes, or radiometals, is necessary for these applications. Additionally, the chelator attaches to a biological targeting vector to locate diseased tissues. While numerous chelators that are suitable for small radiometals have been developed, chelators that are effective for large radiometals are much less common. In this Report, we discuss recent developments in the development of ligands for the chelation of large radiometals, which have potential applications in nuclear medicine.

Keywords: Nanobodies • VHHs • Molecular imaging

Introduction

The evaluation of a primary tumor's response to treatment is yet another application of radionuclide imaging. The efficacy of on-going treatment is determined by anatomical or morphologic changes in the tumour size using traditional methods like mammography or ultrasound. These methods require up to three cycles of treatment before any conclusions can be drawn. By providing functional information, radionuclide imaging can enable an early evaluation of the treatment before the tumour undergoes any anatomical or morphologic changes. An early assessment of a patient's response to treatment would aid in patient management by allowing for the continuation of treatment for responding patients or the implementation of alternative treatment plans for nonresponding patients [1].

Literature Review

Radionuclide imaging is a type of medical imaging that uses small amounts of radioactive material, called radiopharmaceuticals or radiotracers, to produce images of the body. This type of imaging is commonly used in nuclear medicine, which is a branch of medicine that uses radiation to diagnose and treat diseases. Radiopharmaceuticals are typically administered to the patient by injection, inhalation, or ingestion. Once in the body, the radiopharmaceuticals emit gamma rays, which are detected by specialized cameras called gamma cameras. The gamma cameras produce images that show the distribution of the radiopharmaceuticals in the body, which can reveal information about the function of different organs and tissues. There are several types of radionuclide imaging, each of which uses different radiopharmaceuticals and techniques to produce images of different organs and tissues. Some of the most common types of radionuclide imaging.

***Address for Correspondence:** Léa Berland, Department of Chemistry and Bioengineering, University of Harvard, Cambridge, MA 02138, USA; E-mail: Lea.Bd@gmail.com*

Received: 29 October, 2022, Manuscript No. jnmrt-23-90733; **Editor Assigned:** 31 October, 2022, PreQC No. P-90733; **Reviewed:** 15 November, 2022, QC No. Q-90733; **Revised:** 21 November, 2022, Manuscript No. R-90733; **Published:** 28 November, 2022, DOI: 10.37421/2155-9619.2022.13.516

Discussion

The management and treatment landscape of patients, particularly cancer patients, has been revolutionized by recent medical treatment advancements. Patients with various types of locally advanced or metastatic cancer, including melanoma, lung cancer and numerous blood-borne diseases, have seen their life expectancies significantly increase over the past decade. Despite these encouraging results, patients who remain largely unresponsive and those who experience severe toxic side effects are the current challenges associated with these treatments. We will be closer to developing therapies that are more effective if we gain a deeper understanding of the cellular and molecular mechanisms that underlie these varying responses. Non-invasive imaging methods provide valuable whole-body information with precise targeting for evaluating these mechanisms. Immuno-PET (Positron Emission Tomography) is one such method that makes use of radiolabeled antibodies to locate particular molecules of interest. Because they are the smallest derived antibody fragments, nanobodies have excellent properties for this purpose. As a result, they have been extensively utilized in both preclinical models and, more recently, early-stage clinical studies. Their superiority is due, among other things, to their high affinity and specificity for a target. Additionally, their small size (less than 14 kDa) makes it simple for them to spread throughout the bloodstream and reach tissues uniformly and reliably. The powerful imaging potential of nanobodies will be discussed in this overview, primarily through the lens of imaging malignant tumors but also focusing on their ability to image a wider range of nonmalignant diseases.

A new study9 discovered that essential growth 18F-Fluorodeoxyglucose (FDG) normalized take-up esteem got by entire body positron emanation tomography (PET) diminished in responders after the main round of (not set in stone by pathology results after 6 rounds of treatment). Whole-body PET had a sensitivity of 61% and a specificity of 96% in determining the responders after just one round of chemotherapy, using 60% of the baseline standardized uptake value as the cutoff.

This type of imaging uses radiopharmaceuticals that emit positrons, which are a type of antimatter particle. When a positron encounters an electron in the body, the two particles annihilate each other and produce gamma rays, which are detected by the PET scanner. PET imaging is often used to diagnose and monitor cancer, as well as to evaluate the function of the brain and heart. This type of imaging uses radiopharmaceuticals that emit single photons, which are detected by a gamma camera that rotates around the patient. The SPECT scanner produces 3D images of the body that show the distribution of the radiopharmaceuticals. SPECT imaging is often used to evaluate the function of the heart, brain and other organs.This type of imaging uses radiopharmaceuticals that emit gamma rays, which are detected by a gamma camera that is placed close to the body. Gamma scintigraphy is often used to diagnose gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and inflammatory bowel disease (IBD).

Radionuclide imaging is considered to be a safe and non-invasive technique, as the amount of radiation used is very small and the radiopharmaceuticals are quickly eliminated from the body. However, there are some risks associated with the use of radionuclide imaging, particularly for pregnant women and young children. Pregnant women should avoid radionuclide imaging if possible, as the radiation exposure can potentially harm the developing fetus. If imaging is necessary, the lowest possible dose of radiation should be used and the patient should be advised of the risks and benefits of the procedure. Young children are also at increased risk from radiation exposure, as their bodies are still developing and their cells are more sensitive to radiation damage. As such, radionuclide imaging should only be used in children when it is absolutely necessary and the radiation dose should be carefully monitored [2-5].

Conclusion

Radionuclide imaging is a powerful and non-invasive technique that can provide valuable information about the function of different organs and tissues in the body. While there are some risks associated with this type of imaging, these risks can be minimized by using the lowest possible dose of radiation and carefully selecting patients who are most likely to benefit from the procedure. Overall, radionuclide imaging is an important tool in the diagnosis and treatment of many different types of diseases and disorders and it will likely continue to play a vital role in the future of medicine.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Mallia, Madhava B., Viju Chirayil and Ashutosh Dash. "Improved freeze-dried kit for the preparation of 188ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma." *Appl Radiat Isot* 137 (2018): 147-153.
2. Knapp Jr, F.F. "Rhenium-188-A generator-derived radioisotope for cancer therapy." *Cancer Biother Radiopharm* 13 (1998): 337-349.
3. Mushtaq, A. "Concentration of 99mTcO4−/188ReO4− by a single, compact, anion exchange cartridge." *Nucl Med Commun* 25 (2004): 957-962.
4. Bolzati, Cristina, Alessandra Boschi, Licia Uccelli and Adriano Duatti, et al. "An alternative approach to the preparation of 188Re radiopharmaceuticals from generator-produced [188ReO4]−: efficient synthesis of 188Re (V)-meso-2, 3-dimercaptosuccinic acid." *Nucl Med Biol* 27 (2000): 309-314.
5. Chakravarty, Rubel, Ashutosh Dash, M.R.A. Pillai and Meera Venkatesh, et al. "Post-elution concentration of 188Re by an electrochemical method." *Appl Radiat Isot* 68 (2010): 2302-2305.

How to cite this article: Berland, Léa. "Breast Cancer Detection and Diagnosis Using Radionuclide Techniques and Instruments." J Nucl Med Radiat Ther 13 (2022): 516.